We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Cephalon snubs Valeant, agrees to $6.8bn acquisition by Teva
24 Oct 2011
Executive Summary
Just over a month after receiving a hostile offer from Valeant Pharmaceuticals International Inc., leading biotechnology company Cephalon Inc. has signed a definitive agreement to be acquired instead by Teva Pharmaceutical Industries Ltd. for $81.50 in cash per share, a 45% premium to the ten-day average prior to Valeant’s announcement in late March. The new deal values Cephalon at $6.8bn based on the 76.2mm shares outstanding on April 8, 2011 (the most recent figure available), plus $594mm in assumed debt.
Deal Industry
Biotechnology
Pharmaceuticals
Pharmaceuticals
Specialty Pharmaceuticals
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Includes Contract
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?